Want to see JP:4880 full AI Analyst Report?
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥294.00 - ¥736.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)77.65K
Market Cap
¥6.55B
Enterprise Value¥1.41B
Total Cash (Recent Filing)¥4.71B
Total Debt (Recent Filing)¥56.72M
Price to Earnings (P/E)92.7
Beta0.85
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)0.53
Shares Outstanding19,847,778
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.79
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5
Revenue Forecast (FY)¥3.70B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal financial leverage provides durable resilience for a biotech firm: it reduces refinancing and liquidity risk, preserves optionality for multi-year R&D funding, and strengthens the company’s ability to withstand cyclical revenue swings without forcing asset sales or dilutive financing.
Positive Cash GenerationConsistent positive operating and free cash flow supports long-term operations and pipeline investment without full reliance on external capital. For a cell-technology company, recurring internal cash generation enhances strategic flexibility to fund trials, product development, and commercialization over the next several quarters.
Stable Capital BaseA stable asset and equity base after a prior capital step-up implies an established funding foundation. That stability supports multi-year operational planning and reduces the likelihood of immediate balance-sheet stress, enabling sustained investment into core cell-technology capabilities.
Bears Say
Collapsed Profitability & ReturnsA sharp fall in returns and profitability undermines the company’s ability to generate attractive long-term investor returns and to self-fund growth. Persistently compressed ROE and net margins can constrain reinvestment, slow scaling of commercial programs, and pressure strategic options over the next several quarters.
Weakened And Volatile Cash QualityVolatile free cash flow and a recent mismatch where operating cash did not fully cover earnings signal weakening cash quality. That raises execution risk for sustained R&D and commercialization spending, increases reliance on reserves or financing, and reduces predictability of funding for multi-quarter programs.
Inconsistent Revenue TrendsIrregular revenue patterns indicate uneven market adoption or timing of milestone-driven sales. For a technology-driven biotech, inconsistent top-line trends complicate planning, make operating leverage harder to realize, and raise the risk that recent rebounds may not translate into sustained growth over the medium term.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥294.00 and its highest was ¥736.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥6.55B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Sep 10, 2026 which is in 69 days.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Jun 10, 2026. The company reported ¥1.89 earnings per share for the quarter, beating the consensus estimate of N/A by ¥1.89.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.24%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,847,778 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of ¥1.89 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.631%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―